A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastic castration resistant prostate cancer (ANZUP1603). TheraP Study

Kwan, Edmond (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Ref number: HREC 17/PMCC/85
NMA SSA Ref number: SSA/18/MonH/39
SEO code - 920102 Cancer and Related Disorders

Status	Finished
Effective start/end date	6/02/18 → 5/02/23

Clinical Trial Phase

Phase II